Top > Health and Fitness 
Health and Fitness
| 41. |
Singapore - Quality and Uniformity Differentiates Healthcare Services
|
|
|
Medical tourism industry in Singapore is expected to grow at a CAGR of 9.1% through 2012 to generate total revenue of nearly US$ 1700 Million, said “Asian Medical Tourism Analysis (2008-2012)”, a new research report from RNCOS.
According to the report, although the healthcare cost in Singapore is higher than that in other four major Asian medical tourism markets (India, Malaysia, Philippines and Thailand), the tag of the most developed market gives competitive advantage to its medical tourism market. Besides, the quality of healthcare services in Singapore is much better than other Asian markets; in fact, it is equivalent to the US and Western Europe in some cases, helping the Singaporean medical tourism market to grow.
The other reason why Singapore scores over other Asian majors like Thailand and India is that unlike these countries, where there is a wide gap in infrastructure, resources and hygiene between government and private hospitals, the quality healthcare services provided in Singapore are more or less uniform.
In addition, Singapore is famous worldwide for its rich and diverse cultural heritage that attracts international patients who not only get excellent healthcare service, but also visit some of the unique tourist attractions ranging from spa treatments to golf courses. Another key factor that draws patients to Singapore is a wide spectrum of healthcare services that spread from primary health screening to highly complex (quaternary care) services such as organ transplants and step down recovery program.
“Asian Medical Tourism Analysis (2008-2012)” is a thorough study of the five biggest Asian medical tourism markets (Singapore, India, Thailand, Philippines and Malaysia). It provides comprehensive information comprising statistical data and analysis on the past, present and future potential of these markets. The report also discusses the market size, tourist arrivals, infrastructure, accreditations, cost, and success and risk factors.
The research highlights the fact that all the five Asian markets are different from each other in every segment, including cost, human resources, infrastructure, patient perceptions, competencies and government support.
It also provides forecast on various segments such as medical tourism market by country and medical tourists arrivals by country so that investors can align their investment plans according to the chosen market.
Date Added: May 21, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
Member Reviews |
 |
Visitor Ratings |
 |
Google PR |
 |
|
| 42. |
RNCOS Releases a New Report- Ukraine Pharma - New Opportunities for Growth
|
|
|
RNCOS has recently added a new Market Research Report titled, “Ukraine Pharma - New Opportunities for Growth” to its report gallery. According to the new research report, Ukraine promises to be one of the most lucrative pharmaceutical markets in the world. In 2007, the Ukrainian pharmaceutical market grew by nearly 21% to register revenues in excess of US$ 2 Billion. The market is characterized by an increasing proportion of imported and high-priced drugs. In 2007, the average unit price of drugs sold in Ukraine increased by nearly 20%, strongly pushing the value of pharmaceutical sales, despite a relatively ordinary growth in sales volume.
The future outlook of the industry also seems very positive as the market is expected to be driven by a number of reforms recently proposed by the government. Factors such as increasing penetration of health insurance and increasing disposable incomes of consumers will also fuel growth. The lack of effective price controls and high margins are also expected to lure foreign players in this market. The country’s unstable political environment, however, will be the biggest hurdle for investments. But overall, the market is expected to grow strongly, exceeding US$ 4.5 Billion in revenues by 2012.
This report gives an extensive and objective analysis on the pharmaceutical market of Ukraine. It investigates both the past and present trends in the market, with its main focus on the future trends shaping the industry. The study discusses the performance of both the retail and hospital segments of the pharmaceutical market in detail and based on various present and future indicators, analyzes the future of these segments. This report gives valuable information to manufacturers/investors planning to enter the Ukrainian pharmaceutical market.
The Report Provides Forecasts on
- Macroeconomic Indicators
- Healthcare Indicators
- Population & Demographics
- Disease Profiles
- Total Pharmaceutical Market
- Retail Pharmaceutical Market
- Hospital Pharmaceutical Market
Key Player Profiling
“Ukraine Pharma - New Opportunities for Growth” provides brief profiling on key players, both domestic and foreign, currently operating in the Ukraine pharmaceutical market. This section describes the revenues and growth of players in the total pharmaceutical market, retail market and hospital market. Performance of key drugs in various segments of the market has also been evaluated. Business profiles of top five players, Berlin Chemie, Sanofi Aventis, Novartis, Arterium and Darnitsa, have also been discussed in this report.
For more information visit: http://rncos.com/Report/IM161.htm
Current Industry News: http://www.rncos.com/Blog/
Date Added: May 21, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 44. |
Obesity Market Plagued by Numerous Challenges`
|
|
|
The global prevalence of overweight and obesity is rising at an alarming rate. The same, however, cannot be said about drugs used for treating these indications. Whereas rates of obesity and overweight have increased continuously over the past 50 years, the market for drugs against such indications has only seen failures till date, says “Booming Global Obesity Drug Market”, our new market research report.
According to the report, currently four drugs dominate this market. They are Roche’s Xenical, Abbots Meridia, Sanofi’s Acomplia and GSK’S Alli. All these drugs either suffer from unacceptable side effects or just fail to provide the desired weight loss that consumers had expected from them. Moreover, the biggest hurdle for these drugs is the fact that obesity is still regarded as a lifestyle disorder by most health officials and, as a result, drugs treating obesity doesn’t qualify for reimbursement. Since the price of these drugs can range anywhere between US$ 50 and US$ 200, patients often discontinue after they fail to give the desired results.
Despite its previous failures, however, the future potential for obesity drugs is huge. The future pipeline for obesity drugs is rich with a number of drugs in late phase-II and Phase-III pipelines. With no effective weight loss therapy currently available in the market and the number of overweight and obese patients expected to reach 2 Billion and 600 Million respectively by 2012, the opportunity is tremendous. And if any drug with a high benefit to risk ration manages to reach the market, it will easily become a potential blockbuster.
“Booming Global Obesity Drug Market” is an extensive and objective analysis on the global market for obesity drugs. It investigates both the past and current trends in the global obesity market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of drugs, both in the market and in developing stage.
Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. It can thus give valuable information for manufacturers/investors preparing to enter the market for obesity drugs.
For more information visit: http://www.rncos.com/Report/IM166.htm
Current Industry News: http://www.rncos.com/Blog/
Date Added: Jun 9, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 46. |
US - Obesity Count Rising, Goldmine for Drug Makers
|
|
|
According to a RNCOS research report, “Booming Global Obesity Drug Market”, increasing prevalence of obesity and high unmet needs are driving the US to become one of the most potential markets for obesity drugs.
As per our analysis, the increasing rate of sedentary lifestyles and intake of high calorie food is taking its toll on the health of Americans. In 2007, around 207 Million people living in the US were classified as either overweight or obese. Out of these, more than 100 Million were found to be clinically obese. The figures of overweight and obesity are expected to reach 223 Million by 2012. The increasing prevalence of obesity in the country will in turn raise the prevalence of a number of lifestyle disorders such as diabetes, hypertension and dementia etc to catastrophic levels.
This pathetic condition is not only ringing alarm bells for the healthcare officials, but is also providing leveled field for obesity drug manufacturers. Americans spend around US$ 60 Billion annually on weight loss products. But no product available in the market has been able to provide the desired weight loss with an acceptable safety profile. Obesity drugs that are presently available in the market either suffer from serious side effects or just fail to provide the desired weight loss. More than 30 drugs, however, are undergoing various phase of clinical development wih three drugs in Phase-III development. Thus, any obesity drug if successfully launched in the market and if found to posses desired characteristics can lead to billions of dollars of revenues in no time, says the report.
“Booming Global Obesity Drug Market” is an extensive and objective analysis on the global market for obesity drugs. It investigates both the past and current trends in the global obesity market, and outlines the future trends shaping it up. It comprehensively assesses the performance of drugs, both on the market and in developing stage.
Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. It can thus give valuable information for manufacturers/investors preparing to enter in the market for obesity drugs.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM166.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com
Date Added: Jun 9, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 47. |
India to Conduct 5% Global Clinical Trials by 2012
|
|
|
India is fast becoming one of the biggest hubs for conducting global clinical trials. In 2007, the country conducted around 220 clinical trials, making up for less than 2% of the global clinical trials But according to “Booming Clinical Trials Market in India”, a new research report by RNCOS, a number of factors such as low cost, large patient pool, easy recruitment, strong government support and strengthening of its intellectual property environment will enable India to conduct nearly 5% of the global clinical trials by 2012.
As per the report, India scores well above many other destinations in almost every factor analyzed. For instance, India provides one of the largest patient pools for both infectious and chronic diseases. Moreover, the country has 40 million diabetics, representing the largest in any country. Similarly, India also has one of the highest numbers of patients for other chronic diseases such as cardiovascular, neurological disorders, respiratory disorders and obesity. Apart from chronic disorders, the country also provides one of the largest numbers of patients for such infectious diseases as HIV, malaria and tuberculosis.
The findings of the report suggest that not only does India provide a large patient pool, the recruitment of these patients is also among the fastest in the world. As most of the healthcare costs in India are paid “out of pocket”, a large patient population continues to have unmet medical needs. As a result, they readily volunteer to participate in clinical trials to get free treatment.
“Booming Clinical Trials Market in India” gives an extensive and objective analysis on the Indian clinical trials market. It investigates the advantages and disadvantages India has over other countries to become a global clinical trials hub. The report exhaustively evaluates and compares the key factors that drug companies and CROs look before outsourcing clinical trials to a country. These include factors such as patient pool, regulatory environment, cost, infrastructure, human resources and past performance in conducting clinical trials.
Thus, the report serves as a useful guide for drug manufacturers, CROs, consultants and investors who are planning to enter the Indian clinical trials market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM564.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com
Date Added: Jun 20, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 48. |
Japan - Generics to Account for 29% Pharma Sales Volume by 2013
|
|
|
According to the report “Japanese Generic Market Forecast to 2013”, the generic drugs market in Japan shows immense potential as Japan is amongst the youngest generic markets in the world both in terms of value and volume. But with a number of factors operating in it, the market is expected to grow robustly in the next five years.
The report states that a number of factors will drive the market in future; this includes the generic-friendly nature of the Japanese government which is desperate to cut its surging healthcare costs, patent expiration of a number of blockbuster drugs, wide scale promotion and awareness campaigns of generics, and increasing investment by both domestic and international manufacturers in Japan.
The Japanese generic drugs market grew at a CAGR of 7.5% during 2003-2008, reaching ¥ 333 Billion (US$ 3.5 Billion). The growth rate is slower than the US and some European markets which till recently had been growing at double-digit rates. This is because despite being a young market, the awareness of generics in Japan is comparatively low and generics are still largely perceived as cheaper, low quality alternatives to patented drugs. The nationwide promotion and awareness campaign regarding the safety and efficacy of generics however is expected to change their perception and usage in future.
Our forecast models suggest that the generic drugs market will grow at a CAGR of nearly 9% from 2008 to 2013 to make up for 8% of the pharmaceutical market in terms of sales value and 29% in terms of the sales volume.
“Japanese Generic Market Forecast to 2013” gives extensive and objective analysis on the generic market in Japan. The report investigates both the past and present trends in the market, but its focus is on the future trends shaping the industry. The report also investigates the performance of various players in Japan’s pharmaceutical and generic markets, and analyzes the competitive landscape of the market.
Based on the various present and future indicators, the future scenario of the market has also been analyzed. The report thus gives valuable information to manufacturers/investors preparing to enter the Japanese generic market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM170.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com
Date Added: Jun 20, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 49. |
MV Hospital Promotes Prevention of Childhood Obesity and Diabetes
|
|
|
Hospital for Diabetes & Diabetes Research Centre, Chennai and the WHO collaborating centre in India, launched a campaign titled ‘Campaign on Prevention of Childhood Obesity and Diabetes’ to address this concern. A manual detailing facts and guidelines on prevention of obesity for children was also launched to help cultivate long-term weight control. The manual, an awareness handbook on the subject in the country— Manual on Prevention of Childhood Obesity—was launched by Thangam Thennarasu, Honorable Minister of Education, Tamil Nadu.
Dr Vijay Viswanathan, Managing Director, MV Hospital for Diabetes, said, "The increase of obesity in children in India especially in the urban areas is quite alarming. Therefore, we decided to concentrate on the food habits of children and assist parents in providing their children with a healthy nutritious diet. The manual also has guidelines on physical activity and routines that would not over-stress the child but help stay fit." He requested the Government of Tamil Nadu to support the Institute in performing an impact assessment in the state. The study would form a base for understanding the need for awareness on prevention of childhood obesity and diabetes not just in the state, but for the entire country, he said. "We are planning to submit a memorandum to the Government in this regard and hope to launch the project soon," Dr Viswanathan added.
Goal of treatment for Diabetes :
The main goal of treating diabetes is to lower blood sugar to a normal level. Lowering and controlling blood sugar may help prevent or delay complications of diabetes such as heart disease, kidney disease, blindness and amputation.
High blood sugar can be lowered by diet and exercise and by certain medicines.
Treatment of Type 2 Diabetes with Sitagliptin (Januvia)
Type 2 diabetes is a condition in which body does not make enough insulin, and the insulin that body produces does not work as well as it should. Body can also make too much sugar. When this happens, sugar [glucose] builds up in the blood. This can lead to serious medical problems.
RECENT APPROACH FOR TYPE 2 DIABETES – SITAGLIPTIN (JANUVIA):
*Sitagliptin (Januvia) helps to improve the level of insulin after a meal
*It decreases the amount of sugar made by the body
*It works when blood sugar is high, especially after a meal. This is when the body needs the greatest amount of help in lowering blood sugar. It also lowers blood sugar between meals. *It is unlikely to cause low sugar [Hypoglycemia] because it does not work when blood sugar is low
*It can be used alone or in combination with certain other medicine that lowers blood
sugar along with recommended diet and exercise program
CANNOT BE USED FOR PEOPLE WITH THE FOLLOWING CONDITIONS:
*Type I Diabetes [who needs only insulin]
*Diabetic Ketoacidosis [increased ketones in blood and urine]
*Any kidney problems or any post or present medical problems *Allergy to Sitagliptin
* Children below 18 years of age
* Pregnancy and breast feeding woman
DOSAGES:
*100 mg tablet is available in the market
*Once a day by mouth with or without food
*Diet and exercise can help our body use its blood sugar better. We should follow the
recommended diet, exercise and weight loss program while taking Sitagliptin
SIDE EFFECTS:
Like other medicines, may cause side effects. But it was usually mild and did not cause patient to stop taking Sitagliptin. The side effects reported in patient treated with Sitagliptin were similar to side effects in patient treated with a tablet containing no medication [a placebo].
When used with sulfonylurea like Daonil, low blood sugar [Hypoglycemia] due to sulfonylurea can occur. Lower doses of sulfonylurea medicine may be required.
When Januvia [Sitagliptin] and Metformin [like Glyciphage] were started together the following side effects were reported.
*Diarrhea
*Indigestion
*Flatulence
*Vomiting
*Headache
OTHER EFFECTS OF THE MEDICINE:
*Allergic reaction
*Upper respiratory infection
*Stuffy nose and sore throat
Date Added: Jun 20, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
| 50. |
Advancements in Hernia Surgery
|
|
|
An abdominal hernia is an opening through the muscles of the abdomen that allows the intestines to poke through the muscle wall, forming a visible lump under the skin. When further weakness in the muscle wall allows the opening to grow, more of the intestines are able to protrude and may eventually resist being pushed back into the abdomen. This becomes an incarcerated hernia and can lead to a medical emergency if the opening pinches off the blood supply to the protruding organs. Surgical repair is the only cure for a hernia.
Surgery Before the Patch
Before the advent of the mesh patch, hernias were repaired by opening the abdomen where the muscles were separating and suturing them back together.
One disadvantage of this type of invasive surgery is it requires several weeks for recovery. Because the recovery period is reputed to be long and painful, patients sometimes put off having the operation until living with the pain becomes worse than the fear of surgery and its possible complications. And because most surgeries were simply joining together the two sides of already weakened muscle tissues, the hernia would recur in approximately 10% to 20% of cases.
The First Mesh Patches
Because sewing the weakened muscle tissue back together was not a lasting repair in many cases, surgeons devised a mesh patch that they could attach inside the abdomen behind the weakened area. This resulted in a much sturdier and longer-lasting correction of the hernia. The sterile mesh patch was designed to provide a latticework enabling new tissue to grow and strengthen the area. This approach reduced the recurrence rate, but was still performed using open surgery.
Laparoscopic Surgery
With the increasing use of the laparoscope for abdominal procedures, it wasn’t long before doctors devised a way to place a patch behind a hernia using this minimally invasive method. The laparoscope is a narrow tube with a camera, light, and tiny surgical instruments on one end that can be inserted in the abdomen through a small incision. When the abdomen is slightly inflated using CO2 gas, the surgeon can perform surgical procedures by manipulating the instruments while observing his work on a television screen.
The laparoscopic hernia repair procedure combined all the advantages of a patch with the benefits of a minimally invasive surgery including reduced pain and a much shorter recovery period.
The Minimally Invasive Technique
Despite the benefits of laparoscopic surgery, it’s an expensive procedure because of the specialized equipment required. As a result, medical researchers devised a new minimally invasive approach for implanting a hernia patch. In this technique, the surgeon makes a small incision near the site of the hernia. He inserts a rolled-up patch through the incision and spreads it out in place behind the abdominal wall. Then he adds a couple of sutures to hold the patch in place.
This procedure is typically performed as day-surgery with minimal post-operative pain, a recovery period of just a few days, and an extremely low recurrence rate of around 1% or less.
Advancements in Hernia Patches
With the minimally-invasive technique becoming the surgical method of choice, treatment advances began focusing on the nature of the patch itself. Various patents were granted for different compositions, structures and designs of the mesh fabric for hernia repair patches.
In the early 1990’s, one well-known surgeon, Dr. Robert Kugel, came up with the idea of placing an extremely thin plastic ring inside the patch, so it could be folded and inserted though a small incision, and would then unfold itself once released inside the abdomen. Moreover, the semi-rigid ring made it exceptionally easy to maneuver the patch into place, and his innovations in mesh fabric design created a patch that remained in position without sutures.
By 2001, Dr. Kugel had ten patents to his credit for the function, design, and method of placement of the Kugel Mesh Hernia Patch with the memory recoil ring.
Despite the recall of certain Kugel hernia patches that were defective because of a flaw in the manufacturing process, the Kugel patch and method remains among the state-of-the-art techniques in hernia repair surgery.
For more information, visit http://www.herniapatchadvisor.com
Date Added: Jun 20, 2009 Hits: 0 Rating: 0.00 Votes: 0
|
|
|
Member Reviews |
|
Visitor Ratings |
|
Google PR |
 |
|
|
Editors:
hydrotec
|
